LEADER 05502nam 2200721 450 001 9910132216103321 005 20230519080349.0 010 $a1-118-46877-5 010 $a1-118-46879-1 010 $a1-118-46876-7 035 $a(CKB)3710000000096945 035 $a(EBL)1658805 035 $a(SSID)ssj0001132517 035 $a(PQKBManifestationID)11610992 035 $a(PQKBTitleCode)TC0001132517 035 $a(PQKBWorkID)11167139 035 $a(PQKB)10639831 035 $a(OCoLC)878147451 035 $a(MiAaPQ)EBC1658805 035 $a(DLC) 2014006445 035 $a(Au-PeEL)EBL1658805 035 $a(CaPaEBR)ebr10855754 035 $a(CaONFJC)MIL586306 035 $a(OCoLC)871186971 035 $a(EXLCZ)993710000000096945 100 $a20140412h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aLung cancer /$fedited by Jack A. Roth [and five others] 205 $aFourth edition. 210 1$aHoboken, New Jersey :$cWiley-Blackwell,$d2014. 210 4$dİ2014 215 $a1 online resource (634 p.) 300 $aDescription based upon print version of record. 311 $a1-118-46874-0 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aLung Cancer; Contents; Contributors; Preface; CHAPTER 1 Smoking Prevention and Cessation; Overview; Introduction; Tobacco and lung cancer; Secondhand smoke andlung cancer; Smoking among lungcancer patients; Forms of tobacco; Smoked tobacco; Smokeless tobacco; Recent developments on the tobacco market; Factors explaining tobacco use; Smoking initiation; Smoking prevention; Nicotine addiction; Benefits of quitting; Smoking cessation interventions; Behavioral counseling; Pharmaceutical aids for smoking cessation; Nicotine replacement therapy; Sustained-release bupropion; Varenicline 327 $aCombination therapyUse of medications in pregnancy; Summary; References; CHAPTER 2 Lung Cancer Susceptibility and Risk Assessment Models; Introduction; Epidemiologic risk factors; Family history; Prior inflammatory diseases and disorders; Diet and nutritional risk factors; Genetic susceptibility; Candidate gene approaches; Genome-wide association studies; 6p21 and 12p13; Intermediate phenotypic assays in measuring genetic susceptibility; DNA damage and repair phenotypic assays; Cell cycle phenotypic assays; Phenotypic assays in apoptotic pathways 327 $aEmerging novel biomarkers for LC risk and early detectionLC risk assessment models; An overview of cancer risk prediction models; Concluding remarks; References; CHAPTER 3 Molecular Profiling; Introduction; Techniques used in molecular profiling; DNA sequencing; RNA profiling; Proteomics; Data analysis and statistics; Clinical applications; Early detection and diagnosis; Molecular subclassification and staging; Selection of therapy; Future directions and conclusions; Acknowledgments; References; CHAPTER 4 Somatic Genome Alterations in Human Lung Cancers; Lung cancer genetics overview 327 $aLung adenocarcinoma genomicsMolecular alteration spectra of lung adenocarcinoma; Key genetic alterations in lung adenocarcinoma in a few selected pathways; Genetic correlates of sensitivity and resistance; Germline predisposition; Future directions; Lung squamous cell carcinoma genomics; Introduction and overview of genomic alterations of lung SqCCs; Somatic copy number alterations; Genomic features of small cell lung cancers; Previous molecular findings in SCLC; Large-scale genome analysis studies of SCLC; Biological and clinical implications of SCLC genome alterations; References 327 $aCHAPTER 5 Serum Proteomic BiomarkersNatural history of lung cancer progression and potential utility for biomarkers in the clinic; The blood proteome; Proteomic discovery platforms; Proteomic approaches for discovery and validation of blood biomarkers; MALDI-TOF MS serum analysis for diagnosis; Serum proteomics for response to therapy; Strategies to address serum proteome complexity; Liquid chromatography (LC) tandem mass spectrometry (MS/MS); Targeted proteomics using multiple reaction monitoring (LC MRM MS); Bio-analytical validation of serum protein biomarkers; Circulating autoantibodies 327 $aClinical validation of serum biomarkers 330 $aLung Cancer is a comprehensively revised and expanded edition the well-established, concise, multidisciplinary reference book dealing with advances in lung cancer clinical research and treatment for the clinician. Edited and authored by leading authorities in the field, it is the best concise single source for state-of-the-art diagnosis and treatment of lung cancer. The new fourth edition is now better than ever, incorporating the most recent work in the field of lung cancer research, diagnosis, and treatment. This book has always been well known and highly regarded for its concise pres 606 $aLungs$xDiseases$xDiagnosis 606 $aLungs$xCancer$xTreatment 606 $aLungs$xCancer 606 $aCancer$xDiagnosis 615 0$aLungs$xDiseases$xDiagnosis. 615 0$aLungs$xCancer$xTreatment. 615 0$aLungs$xCancer. 615 0$aCancer$xDiagnosis. 676 $a616.99/424 702 $aRoth$b Jack A. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910132216103321 996 $aLung cancer$91890569 997 $aUNINA